Receptor dimerization, subtype specialization, polymorphisms and disease-linked mutations, pharmacologic “plasticity,” dominant negative effects, new competitive effects, allosteric modulation, and surprising new approaches to pharmacotherapy—these are the themes that appear to be dominating endocrine receptor biology at the cusp of the new millenium. So, can we forecast a new age of receptor-based therapies of endocrine disorders?